Corticosteroids for Posttransplant Immune Reconstitution Syndrome in Cryptococcus gattii Meningoencephalitis: Case Report and Literature Review-Reference-Cited by-同舟云学术

Corticosteroids for Posttransplant Immune Reconstitution Syndrome in Cryptococcus gattii Meningoencephalitis: Case Report and Literature Review

Published:2019-10-23 Issue:11 Volume:6 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Canfield Gregory S¹^ORCID,Henao-Martínez Andrés F¹,Franco-Paredes Carlos¹²^ORCID,Zhelnin Kristen³,Wilson Michael L³^ORCID,Shihadeh Katherine C⁴,Wyles David⁵,Gardner Edward M⁵^ORCID

Affiliation:

1. Department of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, USA

2. Hospital Infantil de Mexico, Federico Gomez, Mexico City, Mexico

3. Deparment of Pathology, Denver Health Medical Center, Denver, Colorado, USA

4. Department of Pharmacy, Denver Health Medical Center, Denver, Colorado, USA

5. Department of Infectious Diseases, Denver Health Medical Center, Denver, Colorado, USA

Abstract

Abstract Cryptococcus gattii represents an emerging fungal pathogen of immunocompromised and immunocompetent hosts in the United States. To our knowledge, this is the first case of posttransplant immune reconstitution syndrome due to C. gattii meningoencephalitis successfully treated with corticosteroids. We also report successful maintenance phase treatment with isavuconazole, a novel triazole, following fluconazole-induced prolonged QT syndrome.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofz460/30268526/ofz460.pdf

Reference33 articles.

1. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America;Perfect;Clin Infect Dis,2010

2. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method;Espinel-Ingroff;Antimicrob Agents Chemother,2015

3. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility;Lockhart;Diagn Microbiol Infect Dis,2012

4. Isavuconazole: a new broad-spectrum triazole antifungal agent;Miceli;Clin Infect Dis,2015

5. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen;Harris;Clin Infect Dis,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Geographical distribution of the Cryptococcus gattii species complex: a systematic review;The Lancet Microbe;2024-08

2. A Fatal Fungal Infection: Cryptococcus gattii (VGI) Meningitis in Texas;Open Forum Infectious Diseases;2022-05-09

3. Immune reconstitution inflammatory syndrome (IRIS) in a patient with neuro pulmonary nocardiosis following hematopoietic cells transplantation (HCT);Journal of Infection and Chemotherapy;2022-02

4. Antifungal Drugs TDM: Trends and Update;Therapeutic Drug Monitoring;2022-02

5. Consensus guidelines for the diagnosis and management of cryptococcosis and rare yeast infections in the haematology/oncology setting, 2021;Internal Medicine Journal;2021-11